IN8bio (INAB) awards director 22,000 stock options at $1.58

Rhea-AI Filing Summary

IN8BIO, INC. director Emily Fairbairn received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in 12 equal monthly installments starting on June 9, 2026 and will in any case be fully vested on the date of the company’s next annual meeting of stockholders, subject to her continued service. These options expire on May 9, 2036, and following this grant she holds 22,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider FAIRBAIRN EMILY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 22,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 22,000 options Exercise price: $1.58/share Total options after grant: 22,000 options +2 more

5 metrics

Stock options granted 22,000 options Grant to director Emily Fairbairn

Exercise price $1.58/share Strike price for granted stock options

Total options after grant 22,000 options Holdings following transaction

Option expiration date May 9, 2036 End of option term

Vesting commencement June 9, 2026 Start of 1/12 monthly vesting schedule

Key Terms

Stock Option (right to buy), exercise price, vest in equal monthly installments, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price of 1.5800 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"shall vest in equal monthly installments commencing on June 9, 2026"

annual meeting of stockholders financial

"fully vested on the date of the Company's next annual meeting of stockholders"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FAIRBAIRN EMILY

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVENUE, SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.58	05/09/2026		A		22,000		(1)	05/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IN8BIO (INAB) report for Emily Fairbairn?

IN8BIO reported that director Emily Fairbairn received a grant of 22,000 stock options. These options give her the right to buy common shares at a fixed exercise price, aligning part of her compensation with future company performance.

How many IN8BIO (INAB) stock options were granted to the director?

Emily Fairbairn was granted 22,000 stock options. Each option represents the right to purchase one share of IN8BIO common stock, subject to vesting conditions and an exercise price set at the time of the grant.

What is the exercise price of Emily Fairbairn’s IN8BIO (INAB) stock options?

The exercise price of Emily Fairbairn’s stock options is $1.58 per share. This is the price she must pay to convert each option into one share of IN8BIO common stock once the options have vested.

When do Emily Fairbairn’s IN8BIO (INAB) stock options vest?

One twelfth of Emily Fairbairn’s options vest in equal monthly installments starting on June 9, 2026. The grant will be fully vested by the company’s next annual stockholder meeting, assuming she continues to provide service through those dates.

When do the granted IN8BIO (INAB) stock options to Emily Fairbairn expire?

The granted stock options to Emily Fairbairn expire on May 9, 2036. After this expiration date, any unexercised options become worthless, so exercises must occur while vested and before the option term ends.

Are Emily Fairbairn’s IN8BIO (INAB) stock options held directly or indirectly?

The Form 4 indicates Emily Fairbairn holds these stock options directly. Direct ownership means the options are recorded in her name rather than through a trust, partnership, or other indirect holding structure.